Literature DB >> 27849466

Descriptive Characteristics and Amputation Rates With Use of Intrepid Dynamic Exoskeleton Orthosis.

Owen Hill1, Lakmini Bulathsinhala1, Susan L Eskridge2, Kimberly Quinn2, Daniel J Stinner1.   

Abstract

Advancements in ankle-foot orthotic devices, such as the Intrepid Dynamic Exoskeletal Orthosis (IDEO), are designed to improve function and reduce pain of the injured lower extremity. There is a paucity of research detailing the demographics, injury patterns and amputation outcomes of patients who have been prescribed an IDEO. The purpose of this study was to describe the demographics, presenting diagnosis and patterns of amputation in patients prescribed an IDEO at the Center for the Intrepid (CFI). The study population was comprised of 624 service members who were treated at the CFI and prescribed an IDEO between 2009 and 2014. Data were extracted from the Expeditionary Medical Encounter Database, Defense Manpower Data Center, Military Health System Data Repository, and CFI patient records for demographic and injury information as well as an amputation outcome. The most common injury category that received an IDEO prescription was injuries at or surrounding the ankle joint (25.0%), followed by tibia injuries (17.5%) and nerve injuries below the knee (16.4%). Over 80% of the sample avoided amputation within a one year time period using this treatment modality. Future studies should longitudinally track IDEO users for a longer term to determine the long term viability of the device. Reprint &
Copyright © 2016 Association of Military Surgeons of the U.S.

Entities:  

Mesh:

Year:  2016        PMID: 27849466     DOI: 10.7205/MILMED-D-16-00281

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  1 in total

1.  Passive-dynamic ankle-foot orthosis improves medium-term clinical outcomes after severe lower extremity trauma.

Authors:  Peter Ladlow; N Bennett; R Phillip; S Dharm-Datta; L McMenemy; A N Bennett
Journal:  J R Army Med Corps       Date:  2018-11-09       Impact factor: 1.285

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.